Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5 clinical trials
Featured trial
Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive (DART4MM)

Aim of this study is to evaluate Daratumumab effect on MRD-positive patients with Multiple Myeloma (MM) who achieved >VGPR after any therapy (ASCT, VMP, Rev-Dex). Daratumumab 16 mg/kg administered at weekly intervals for 8 weeks, then every 2 weeks for an additional 16 weeks, will be given to 50 MM …

  • 0 views
  • 03 Dec, 2023
  • 1 location
CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children

Adding bortezomid during the consolidation:The very early or early bone marrow relapse has low remission rate. Previous case studies showed that Bortezomib, a proteasome inhibitor, may achieve remission in refractory ALL, 80% remission in B-ALL with combination of chemotherapy and bortezomib.

leukemia
remission
flow cytometry
b-cell acute lymphoblastic leukemia
leukemic cells
  • 0 views
  • 16 Feb, 2024
  • 1 location
Evaluation of Efficacy and Safety of Belantamab Mafodotin Bortezomib and Dexamethasone Versus Daratumumab Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.

refractory multiple myeloma
daratumumab
multiple myeloma
belantamab mafodotin
hair thinning
  • 0 views
  • 16 Feb, 2024
  • 14 locations
A Multicentre Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment

This study is to see if the standard of care subcutaneous injection of bortezomib can safely be administered at home by the patient or caregiver. All tests and assessments are based on standard of care procedures.

bortezomib
cancer
multiple myeloma
  • 0 views
  • 16 Feb, 2024
  • 1 location
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of VR-CAP (Velcade and Rituximab-Cyclophosphamide, Epirubicin and Prednisone) in the first-line treatment for patients with marginal zone lymphoma.

marginal zone lymphoma
epirubicin
prednisone
cyclophosphamide
lymphoma
  • 0 views
  • 05 Aug, 2020